SCHEMBL15092141

SCHEMBL15092141

CC(C)(C)OC(=O)NC1CCN(c2ccc(N)c(Br)c2)C1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SUV39H2 Q9H5I1 10/20 0.48
HDAC3 O15379 1/20 0.47
HDAC1 Q13547 1/20 0.47
HDAC2 Q92769 1/20 0.47
CTSK P43235 2/20 0.46
MAP4K4 O95819 2/20 0.45
PIM1 P11309 1/20 0.45
PIM3 Q86V86 1/20 0.45
PIM2 Q9P1W9 1/20 0.45
BTK Q06187 1/20 0.44
CKS1B P61024 1/20 0.42
SKP1 P63208 1/20 0.42
SKP2 Q13309 1/20 0.42
CYP2C9 P11712 1/20 0.42
HSD11B1 P28845 1/20 0.42
PDE10A Q9Y233 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15092142 1.00 SUV39H2 (0.48) SUV39H2HDAC3HDAC1HDAC2CTSK
SCHEMBL7242505 0.90 SUV39H2 (0.50) SUV39H2HDAC3HDAC1HDAC2CTSK
SCHEMBL7235725 0.86 SUV39H2 (0.48) SUV39H2HDAC3HDAC1HDAC2CTSK
SCHEMBL3708015 0.85 CTSK (0.52) SUV39H2HDAC3HDAC1HDAC2CTSK
SCHEMBL30936771 0.84 CTSK (0.51) SUV39H2CTSKMAP4K4PIM1PIM3
SCHEMBL31331790 0.83 DRD2 (0.45) SUV39H2HDAC3HDAC1HDAC2CTSK
SCHEMBL15093029 0.83 SUV39H2 (0.46) SUV39H2CTSKPIM1PIM3PIM2
SCHEMBL2578938 0.83 SUV39H2 (0.46) SUV39H2CTSKPIM1PIM3PIM2
SCHEMBL31331951 0.83 DRD2 (0.45) SUV39H2HDAC3HDAC1HDAC2CTSK
SCHEMBL14892758 0.83 CKS1B (0.48) SUV39H2HDAC3HDAC1HDAC2CTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9453025-B2 Tricyclic compounds and PBK inhibitors containing the same ONCOTHERAPY SCIENCE, INC. (JP) 2016-09-27 US disclosed
EP-2552206-B1 TRICYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME ONCOTHERAPY SCIENCE INC (JP) 2015-07-22 EP disclosed
US-20150183799-A1 Tricyclic Compounds and PBK Inhibitors Containing the Same ONCOTHERAPY SCIENCE INC (JP) 2015-07-02 US disclosed
US-8962648-B2 Tricyclic compounds and PBK inhibitors containing the same ONCOTHERAPY SCIENCE, INC. (JP) 2015-02-24 US disclosed
US-20130178459-A1 TRICYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME ONCOTHERAPY SCIENCE, INC. (JP) 2013-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130178459-A1 TRICYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME PBDC1, SBK1, PLK2 SUV39H2 2668/4885HDAC3 478/4885HDAC1 457/4885
US-20150183799-A1 Tricyclic Compounds and PBK Inhibitors Containing the Same PBDC1, SBK1, PLK2 SUV39H2 2668/4885HDAC3 478/4885HDAC1 457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.